Intarcia
Intarcia Therapeutics was a biopharmaceutical company that developed the Medici Drug Delivery System for chronic diseases, including type 2 diabetes.
Secondary Market Price
How Intarcia Measures Up
To help you manage your Intarcia equity, Prospect has run the company through our machine learning model.
Prospect Rating
--
This rating reflects our belief in this company's potential to grow to that many times its current value in 4 years. For an employee with stock, this rating suggests a potential return on equity, but it also comes with some risk.
Exit Risk
--
Our rating is a reflection of the likelihood of this company achieving a liquidity event for its employees based on the quality of investors, funding stage, founders, and more.
Funding Stage
Series EE
A company’s funding stage reflects how established it is, how quickly it is scaling, and the average impact an employee may have when joining.
Secondary Market Price Chart
Create a free account to unlock real-time secondary market prices and future projections of Intarcia's value.
Sign up to Unlock the Latest DataData will be available soon.
Sign up to receive notifications when it is available.
Prospect Projected Future Intarcia Prices
Prospect’s machine learning model has been trained on the same data top-tier investors use to project the likely range of outcomes for Intarcia's equity. Create a free account to view 10th-90th percentile projections over 2, 4, and 6 years.
Powerful tools to earn more from your equity
Company Description
Intarcia Therapeutics was a biopharmaceutical company that focused on developing therapies for chronic diseases. The company's work centered on its Medici Drug Delivery System, a platform designed for the prevention and management of chronic conditions. Key products developed by Intarcia include ITCA 650, a delivery device for type 2 diabetes, and OMEGA DUROS, an interferon delivery device for treating Hepatitis C. Founded in 1997, the company was headquartered in Boston, Massachusetts, with other locations in Hayward, California, and Durham, North Carolina. According to public records, the company is now closed.
While the company's stated mission was to redesign the treatment and prevention of chronic diseases, there is no information available regarding future plans or recent announcements. Its status as a closed entity indicates that business activities have ceased.
- New Enterprise Associates
- Venrock
- New Leaf Venture Partners
- RA Capital Management
- Farallon Capital Management
- Foresite Capital
- The Baupost Group
- Bill & Melinda Gates Foundation
- Co-Founder, David Franklin
- Co-Founder, James M. Ahlers
- Co-Founder, Thomas Alessi
Peer Group Comparison
Vs Peer Group of >$4B Startups
Frequently Asked Questions
Joining Anduril as an employee is another way to acquire equity, typically through stock options included in compensation packages.
Is Intarcia worth joining?
Deciding whether to join a startup involves assessing the complete compensation package, including the potential upside of your equity grant. Understanding the future value of that equity is crucial, and a platform like Prospect provides predictive modeling to help you analyze the financial outcomes.
What should I do with my Intarcia stock?
Managing private company stock involves complex decisions around tax implications, exercise timing, and diversification. Using a dedicated platform like Prospect can provide you with a personalized strategy to help optimize the value of your shares and minimize your tax burden.
Can you sell Intarcia stock?
Since Intarcia is a private company, selling stock is typically restricted to specific events like tender offers or secondary market sales. Platforms such as Prospect provide tools to help you decide how much to sell and which shares are most tax-efficient to offload during these opportunities.
How can I find the value of my Intarcia stock?
Valuing stock in a private company is challenging because it doesn’t trade on a public exchange. You can use a platform like Prospect to upload your equity grants and use their predictive models to forecast your stock's potential future value.
What is Intarcia's equity worth?
The precise worth of your Intarcia equity depends on the company's latest 409A valuation and the specifics of your grant. To understand the potential net value after taxes and model different financial scenarios, you can use an equity management platform like Prospect.
What is Intarcia's stock ticker symbol?
As a privately held company, Intarcia does not have a stock ticker symbol. Ticker symbols are only assigned to companies once they begin trading on a public stock exchange.
Can I buy or sell Intarcia stock?
Selling stock in a private company like Intarcia is generally limited to company-approved events like tender offers, while buying shares is typically not an option for most individuals. If you are an employee, platforms like Prospect provide tools to help you navigate selling opportunities and exercise your existing options tax-efficiently.
What is the criteria to buy or invest in Intarcia stock?
Investing in a private company is typically reserved for accredited investors, venture capital firms, or employees who receive equity as compensation. If you are an employee with stock options or RSUs, you can use a service like Prospect to manage and optimize your holdings, rather than to make a new investment.
